Dr. Bhatia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
825 Eastlake Ave E
Mailstop CE2-112
Seattle, WA 98109Phone+1 206-606-7222- Is this information wrong?
Summary
- Dr. Shailender Bhatia is a medical oncologist in Seattle, WA and is affiliated with University of Washington (UW), and Fred Hutchinson Cancer Center (FHCC.) He serves as the Clinical and Clinical Research Director of the Melanoma and Renal Cancer Program at FHCC. Dr Bhatia received his medical degree from All India Institute of Medical Sciences (AIIMS) and subsequently completed hematology-oncology training at UW/FHCC. He has been practicing oncology for >15 years. He specializes in skin cancers (including melanoma and Merkel cell carcinoma) and has led numerous cutting-edge clinical trials of immunotherapy in skin cancers, many of which led to FDA-approval of new agents. He has more than 100 publications, which have over 20,000 citations.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2008
University of ConnecticutResidency, Internal Medicine, 2001 - 2004
All India Institute of Medical SciencesClass of 2000
Certifications & Licensure
WA State Medical License 2004 - 2025
CT State Medical License 2004 - 2005- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma Start of enrollment: 2023 Nov 08
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Prognosis of Merkel cell carcinoma patients with autoimmune disorders, other types of immune dysfunction, or immunocompetent status: Analysis of 762 patients.Song Y Park, Daniel S Hippe, Lauren Zawacki, Marika Bierma, Shailender Bhatia, Paul Nghiem, Lisa C Zaba, Namrata Singh> ;Journal of the American Academy of Dermatology. 2024 May 1
- Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma.Lisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy, Dane Fritzsche, Andrea Perdue, Julia Majovski, Thomas Pulliam, Daniel A ...> ;Cancer Immunology, Immunotherapy. 2023 Dec 1
- Increased risk of recurrence and disease-specific death following delayed postoperative radiation for Merkel cell carcinoma.Nora A Alexander, Stephanie K Schaub, Peter H Goff, Daniel S Hippe, Song Y Park, Kristina Lachance, Marika Bierma, Jay J Liao, Smith Apisarnthanarax, Shailender Bhatia...> ;Journal of the American Academy of Dermatology. 2024 Feb 1
- Join now to see all
Press Mentions
Fred Hutch at ASCO: New Insights on Financial Toxicity, Combination Therapies for Cancer and the Need for Targeted Breast Cancer Therapies in UgandaMay 26th, 2023- Merck Could Keep Its Patent Edge by Shifting Keytruda Cancer Drug to a Simple ShotDecember 2nd, 2022
- Exploring Immunotherapy for the Treatment of Merkel Cell Carcinoma: Shailender Bhatia, MD, and Ciara Kelly, MBBCh, BAOJuly 6th, 2021
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
UW Medicine/University of Washington Medical CenterSeattle, Washington
Fred Hutchinson Cancer CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
